A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

BACKGROUND: Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with no need f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Infect Dis Ther
Päätekijät: Van Hise, Nicholas, Petrak, Russell M., Skorodin, Nathan C., Fliegelman, Robert M., Anderson, Michael, Didwania, Vishal, Han, Alice, Shah, Kairav, Chundi, Vishnu, Hines, David, Roig, Ingrid, Kalra, Apoorv
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7680490/
https://ncbi.nlm.nih.gov/pubmed/33063176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-020-00351-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia